Aging with multiple sclerosis

Physical Medicine and Rehabilitation Clinics of North America

Volumn 21, Issue 2, 2010, Pages 403-417

  Stern, Michelle ^a   Sorkin, Lyssa ^b   Milton, Kelly ^a   Sperber, Kevin ^a  

^a New York Presbyterian Hospital ^*  (United States)

^b New York Presbyterian Columbia Cornell Residency Program   (United States)

Author keywords

Aging; Disability; MS; Pain; Progressive condition

Indexed keywords

AMANTADINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; AZATHIOPRINE; BACLOFEN; BENZODIAZEPINE DERIVATIVE; BETA1A INTERFERON; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CANNABINOID; CARBAMAZEPINE; CLADRIBINE; COPAXANE; CORTICOSTEROID; DULOXETINE; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; IRON; METHYLPHENIDATE; MITOXANTRONE; MODAFINIL; NARCOTIC ANALGESIC AGENT; NATALIZUMAB; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; SPASMOLYTIC AGENT; STEROID; TIZANIDINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AGING; ANEMIA; ANXIETY; BLADDER DYSFUNCTION; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CARDIOMYOPATHY; CEREBELLUM DISEASE; CEREBROSPINAL FLUID EXAMINATION; CHEST TIGHTNESS; CHRONIC DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; CONTRAST ENHANCEMENT; DEPRESSION; DIABETES MELLITUS; DIABETIC NEUROPATHY; DIAGNOSTIC VALUE; DISABILITY; DISEASE CLASSIFICATION; DISEASE COURSE; DRIVING ABILITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; ENTEROPATHY; EVOKED RESPONSE; EXERCISE; FALLING; FAMILY; FATIGUE; FIBROMYALGIA; FLU LIKE SYNDROME; FLUID RETENTION; FLUSHING; HEART DISEASE; HEART PALPITATION; HEART RATE; HEAT INTOLERANCE; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE REACTION; LETHARGY; LEUKOPENIA; LIFESPAN; LIVER FUNCTION TEST; LIVER INJURY; MALIGNANT NEOPLASTIC DISEASE; MOOD; MORBIDITY; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NAUSEA; NEUROPATHIC PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; OSTEOPOROSIS; PAIN; PRIORITY JOURNAL; PROGNOSIS; RESPIRATION DEPRESSION; REVIEW; SENSORY DYSFUNCTION; SEXUAL DYSFUNCTION; SIDE EFFECT; SPASTICITY; TECHNICAL AID; VISUAL DISORDER;

ADAPTATION, PHYSIOLOGICAL; ADAPTATION, PSYCHOLOGICAL; AGED; AGING; DISABILITY EVALUATION; DISABLED PERSONS; FEMALE; HUMANS; INTERPERSONAL RELATIONS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PHYSICAL THERAPY MODALITIES; QUALITY OF LIFE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE;

EID: 77952975482     PISSN: 10479651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pmr.2009.12.008     Document Type: Review

References (59)

1. Williams R., Rigby A.S., Airey M., et al. Multiple sclerosis: its epidemiological, genetic, and health care impact. J Epidemiol Community Health 1995, 49:563-569.
2. Frohman E. Multiple sclerosis. Med Clin North Am 2003, 87:867-897.
3. Hauser S., Goodkin D. Multiple sclerosis and other demyelinating diseases. Harrison's principles of internal medicine 2001, 1096-1133. McGraw-Hill, Minneapolis (MN). 15th Edition. E. Braunwald, A. Fauci, D. Kasper (Eds.).
4. Trojano M. Age-related disability in multiple sclerosis. Ann Neurol 2002, 51:475-480.
5. Joy J., Johnston R. Characteristics and management of major symptoms in multiple sclerosis current status and strategies for the future 2001, National Academy Press, Washington, DC, p.115-76.
6. Paty D. Initial symptoms. Multiple sclerosis: diagnosis, medical management, and rehabilitation 2000, 75-79. Demos, New York. J. Burks, K. Johnson (Eds.).
7. Hazelwood M., Fielstein E. Physiological aspects of aging. Physical medicine and rehabilation: state of the art review rehabilitation and the aging population 1990, 19-28. Hanley and Belfus 4, Philadelphia. F. Maloney, K. Means (Eds.).
8. O'Connor P., Canadian Multiple Sclerosis Working Group Key issues in the diagnosis and treatment of multiple sclerosis. An overview. Neurology 2002, 59:S1-33.
9. Weinshenker B.G. Natural history of multiple sclerosis. Ann Neurol 1994, 36(Suppl):S6-11.
10. Bergamaschi R. Prognostic factors in MS. Int Rev Neurobiol 2007, 79:423-447.
11. Amato M.P., Ponziani G., Bartolozzi M.L., et al. A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J Neurol Sci 1999, 168:96-106.
12. Bashir K., Hadley M.N., Whitaker J.N. Surgery for spinal cord compression in multiple sclerosis. Curr Opin Neurol 2001, 14(6):765-769.
13. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996, 46:907-911.
14. Joy J., Johnston R. Clinical and biological features in multiple sclerosis current status and strategies for the future 2001, National Academy Press, Washington, DC, p. 29-114.
15. Miller D. Magnetic resonance imaging in multiple sclerosis. Multiple sclerosis therapeutics 2003, P81-P97. Martin Dunitz, New York. J. Cohen, R. Rudick (Eds.).
16. Polliak M., Barak Y., Achiron A. Late-onset multiple sclerosis. J Am Geriatr Soc 2001, 49:168-171.
17. Noseworthy J., Paty D., Wonnacott T., et al. Multiple sclerosis after age 50. Neurology 1983, 33:1537-1544.
18. Solero C. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology 2004, 63(5):919-921.
19. Cobble N., Miller E., Grigsby J. Aging with multiple sclerosis. Rehabilitation of the aging and elderly patient 1994, 427-439. Williams and Wilkins, Philadelphia. G. Felsenthal, S. Garrison, F. Steinberg (Eds.).
20. Ehde D.M., Jensen M.P., Engel J.M., et al. Chronic pain secondary to disability: a review. Clin J Pain 2003, 19(1):3-17.
21. Jeffrey D. Pain and dysthesia. Multiple sclerosis: diagnosis, medical management, and rehabilitation 2000, 425-431. Demos, New York. J. Burks, K. Johnson (Eds.).
22. Boop W. Pain management in the geriatric patient. Physical medicine and rehabilation: state of the art review rehabilitation and the aging population 1990, 83-92. Hanley and Belfus 4, Philadelphia. F. Maloney, K. Means (Eds.).
23. Mancini M. Duloxetine in the management of elderly patients with major depressive disorder: an analysis of published data. Expert Opin Pharmacother 2009, 5(10):847-860.
24. Mostert S., Kesselring J. Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Mult Scler 2002, 8:161-168.
25. Willmott C. Safety of methylphenidate following traumatic brain injury: impact on vital signs and side-effects during inpatient rehabilitation. J Rehabil Med 2009, 41(7):585-587.
26. Krupp L. Fatigue in multiple sclerosis. Multiple sclerosis therapeutics 2003, 599-608. Martin Dunitz, New York. J. Cohen, R. Rudick (Eds.).
27. Van den Noort, Fisk J.D., Pontefract A., et al. The impact of fatigue on patients with MS. Can J Neurol Sci 1994, 21:9-14.
28. Minden S., Frumin M., Erb J. Treatment of disorders of mood and affect in multiple sclerosis. Multiple sclerosis therapeutics 2003, 651-689. Martin Dunitz, New York. J. Cohen, R. Rudick (Eds.).
29. Sadovnick A.D., Eisen K., Ebers G.C., et al. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991, 41:1193-1196.
30. Feinstein A. An examination of suicidal intent in patients with multiple sclerosis. Neurology 2002, 59:674-678.
31. Rao S.M. Neuropsychology of MS. Curr Opin Neurol 1995, 8(3):216-220.
32. Bolbholz J.A., Rao S. Cognitive decline in MS: an eight year longitudinal study. J Int Neuropsychol Soc 1998, 16:435-440.
33. Rao S.M., Hammeke T.A., McQuillen M.P., et al. Memory disturbance in chronic progressive MS. Arch Neurol 1984, 41:625-631.
34. Rao S., Leo G., Bernardin L., et al. Cognitive dysfunction in MS: I frequency, patterns and prediction. Neurology 1991, 41:685-691.
35. Amato M.P., Ponzianni G., Pracucci G., et al. Cognitive impairments in early-onset MS: pattern predictors and impact on every day life in a 4-year follow-up. Arch Neurol 1995, 52:168-172.
36. Amato M.P., Ponzianni G., Siracusa G., et al. Cognitive dysfunction in early-onset MS: a reappraisal after 10 years. Arch Neurol 2001, 58:1602-1606.
37. Schwid S. Management of cognitive impairments in MS. Multiple sclerosis therapeutics 2003, 715-725. Martin Dunitz, New York. J. Cohen, R. Rudick (Eds.).
38. Frohman E., Zimmerman C. Neuro-opthalmic signs and symptoms. Multiple sclerosis: diagnosis, medical management, and rehabilitation 2005, 341-377. Demos, New York. J. Burks, K. Johnson (Eds.).
39. DasGupta R., Fowler C.J. Sexual and urological dysfunction in multiple sclerosis: better understanding and improved therapies. Curr Opin Neurol 2002, 15(3):271-278.
40. Wiesel P.H., Norton C., Glickman S., et al. Pathophysiology and management of bowel dysfunction in multiple sclerosis. Eur J Gastroenterol Hepatol 2001, 13(4):441-448.
41. Zorzon M., Zivadinov R., Bragadin L.M., et al. Sexual dysfunction in MS: a 2-year follow-up study. J Neurol Sci 2001, 187:1-5.
42. DeBolt L., McCubbin J. The effects of home-based resistance exercise on balance, power and mobility in adults with multiple sclerosis. Arch Phys Med Rehabil 2004, 85:290-297.
43. Cosman F., Nieves J., Komar L., et al. Fracture history and bone loss in patients with MS. Neurology 1998, 51(4):1161-1165.
44. Kannus P., Parkkari J., Niemi S., et al. Prevention of hip fracture in elderly people with the use of a hip protector. N Engl J Med 2000, 343:1506-1513.
45. Shannon F.J. Total knee replacement in patients with multiple sclerosis. Knee 2004, 11:485-487.
46. Slawta J.N., McCubbin J.A., Wilcox A.R., et al. Coronary heart disease risk between active and inactive women with multiple sclerosis. Med Sci Sports Exerc 2002, 34(6):905-912.
47. Metz L.M., McGuinness S.D., Harris C. Urinary tract infections may trigger relapse in multiple sclerosis. Axone 1998, 19(4):67-70.
48. American Cancer Society statistics. 2009.
49. Bahmanyar S., Montgomery S.M., Hillert J., et al. Cancer risk among patients with multiple sclerosis and their parents. Neurology 2009, 72:1170-1177.
50. Lebrun C., Debouverie M., Vermersch P., et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler 2008, 14:399-405.
51. Noseworthy J.H. Management of multiple sclerosis: current trials and future options. Curr Opin Neurol 2003, 16(3):289-297.
52. Ghalie R.G., Edan G., Laurent M., et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002, 59:909-913.
53. O'Connor P. Natalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosis. Expert Opin Biol Ther 2007, 7(1):123.
54. Beutler E., Sipe J.C., Romine J.S., et al. The treatment of chronic progressive MS with cladribine. Proc Natl Acad Sci U S A 1996, 93(4):1716-1720.
55. Galetta S.L., Markowitz C., Lee A.G. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. Arch Intern Med 2002, 162:2161.
56. Strobel W., Rumrill D., Hennessey M. Multiple sclerosis: a guide for rehabilitation and health care professionals 2002, Charles C Thomas, Springfield (IL), p. 179-208.
57. Bobholz J., Rao S. Cognitive dysfunction in MS a review of recent developments. Curr Opin Neurol 2003, 16(3):283-288.
58. Schultheis M., Garay E., DeLuca J. The influence of cognitive impairment on driving performance in MS. Neurology 2001, 56(8):1089-1094.
59. Schultheis M., Weisser V., Manning K., et al. Driving behaviors among community-dwelling persons with multiple sclerosis. Arch Phys Med Rehabil 2009, 90:975-981.